On a relative basis, the stock has outperformed the S&P 500 by 2.56% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 0.73% in the last 1 week, and is up 4.22% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The company shares have dropped -48.76% from its 1 Year high price. On Jul 23, 2015, the shares registered one year high at $127.00 and the one year low was seen on Mar 16, 2016. The 50-Day Moving Average price is $60.63 and the 200 Day Moving Average price is recorded at $63.10.
The stock has recorded a 20-day Moving Average of 5.5% and the 50-Day Moving Average is 2.75%.
Mallinckrodt plc (NYSE:MNK): stock turned positive on Friday. Though the stock opened at $62, the bulls momentum made the stock top out at $62.53 level for the day. The stock recorded a low of $60.9691 and closed the trading day at $62.29, in the green by 1.33%. The total traded volume for the day was 822,496. The stock had closed at $61.47 in the previous days trading.
In an insider trading activity, Harbaugh Matthew K, CFO of Mallinckrodt Plc, executed a transaction worth $29,685 on May 10, 2016. A total of 500 shares were purchased at an average price of $59.37. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered.
Mallinckrodt public limited company (Mallinckrodt) is a global specialty pharmaceuticals company. The Company develops, manufactures, markets and distributes both branded and generic specialty pharmaceuticals, active pharmaceutical ingredients (API) and diagnostic imaging agents. The Company uses its API products in the manufacture of its generic pharmaceuticals and also sells them to other pharmaceutical companies. The Company operates through two segments: Specialty Pharmaceuticals and Global Medical Imaging. The Companys Specialty Pharmaceuticals segment develops, manufactures and sells, through its Brands business, drugs, including EXALGO (hydromorphone HCl) Extended-Release Tablets and GABLOFEN. The Companys Global Medical Imaging segment develops, manufactures and markets contrast media and delivery systems (CMDS). The Company offers INOMAX Total Care (inhaled nitric oxide), a neonatal critical care product.